CRIS Current Research Information System

DE SIMONE, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.918
NA - Nord America 4.639
EU - Europa 3.314
SA - Sud America 265
AF - Africa 244
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.387
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.585
VN - Vietnam 1.453
SG - Singapore 1.300
CN - Cina 1.209
IT - Italia 827
GB - Regno Unito 806
DE - Germania 392
HK - Hong Kong 319
SE - Svezia 308
IN - India 240
FR - Francia 202
RU - Federazione Russa 181
BR - Brasile 178
IE - Irlanda 125
KR - Corea 103
JP - Giappone 86
CI - Costa d'Avorio 80
UA - Ucraina 78
ZA - Sudafrica 70
FI - Finlandia 63
NL - Olanda 60
EE - Estonia 58
TG - Togo 44
AR - Argentina 36
CH - Svizzera 35
CA - Canada 33
BG - Bulgaria 31
BE - Belgio 29
ID - Indonesia 29
PL - Polonia 25
JO - Giordania 23
SC - Seychelles 22
PH - Filippine 18
TR - Turchia 18
ES - Italia 17
TW - Taiwan 17
BD - Bangladesh 16
TH - Thailandia 15
EC - Ecuador 14
HR - Croazia 14
PK - Pakistan 14
MX - Messico 13
AT - Austria 10
CO - Colombia 10
CZ - Repubblica Ceca 10
SA - Arabia Saudita 10
CL - Cile 8
RO - Romania 8
VE - Venezuela 8
IR - Iran 7
NG - Nigeria 7
GR - Grecia 6
HU - Ungheria 6
PY - Paraguay 6
AU - Australia 5
IL - Israele 5
IQ - Iraq 5
LB - Libano 5
PT - Portogallo 5
SM - San Marino 5
UZ - Uzbekistan 5
EG - Egitto 4
MY - Malesia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DZ - Algeria 3
HN - Honduras 3
KE - Kenya 3
LT - Lituania 3
MA - Marocco 3
NP - Nepal 3
PS - Palestinian Territory 3
TN - Tunisia 3
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
MD - Moldavia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
BJ - Benin 1
BN - Brunei Darussalam 1
DK - Danimarca 1
ET - Etiopia 1
EU - Europa 1
GM - Gambi 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MZ - Mozambico 1
NA - Namibia 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 13.387
Salva come PNG Salva come JPEG
Città #
Singapore 906
Southend 694
Ashburn 459
Fairfield 384
Chandler 378
Ho Chi Minh City 344
Hong Kong 302
Hanoi 281
Dong Ket 255
Santa Clara 251
Bologna 237
San Jose 232
Houston 214
Hefei 182
Ann Arbor 181
Wilmington 180
Seattle 179
Woodbridge 172
Princeton 156
Beijing 143
Cambridge 133
Dublin 124
Boardman 116
Seoul 88
Abidjan 80
Lauterbourg 78
Nanjing 73
Tokyo 71
Westminster 68
Dallas 65
Padova 62
Los Angeles 56
Helsinki 51
Berlin 49
Jinan 47
Redmond 46
Da Nang 44
Lomé 44
Cesena 42
New York 41
Redondo Beach 40
Haiphong 36
Turin 35
Buffalo 33
Munich 32
Saint Petersburg 32
Tianjin 32
Guangzhou 31
Milan 30
Shenyang 30
Medford 29
San Diego 29
Brussels 28
Changsha 27
Sofia 27
Bengaluru 26
Falls Church 26
Council Bluffs 25
Rimini 25
Zhengzhou 25
Hebei 24
Amman 23
Bern 23
Forlì 22
Hangzhou 22
Hải Dương 22
Bremen 21
Carpi 21
Frankfurt am Main 21
Hyderabad 21
Rome 21
Biên Hòa 20
São Paulo 19
Dearborn 18
Jiaxing 18
London 18
Shanghai 18
Phoenix 17
Chicago 16
Nanchang 16
Amsterdam 15
Jakarta 14
Nha Trang 14
Orem 14
Warsaw 14
Yubileyny 14
Haikou 13
Jacksonville 13
Falkenstein 12
Ninh Bình 12
Norwalk 12
Nuremberg 12
Taizhou 12
Can Tho 11
Ha Long 11
Thái Bình 11
Thái Nguyên 11
Xi'an 11
Bắc Giang 10
Denver 10
Totale 8.753
Salva come PNG Salva come JPEG
Nome #
3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease 423
Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease. 394
Advanced analytical methodologies in Alzheimer's disease drug discovery 290
Correction: Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent to Combat Alzheimer's Disease (ACS Medicinal Chemistry Letters (2019) 10: 4 (469−474) DOI: 10.1021/acsmedchemlett.8b00507) 284
AR-A014418-based dual Glycogen Synthase Kinase 3β/Histone Deacetylase inhibitors as potential therapeutics for Alzheimer's disease 263
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: structure-based design, synthesis, and biological evaluation 255
PROTAC-INDUCED GLYCOGEN SYNTHASE KINASE 3B DEGRADATION 235
Reversible human serum albumin binding of lipocrine: a circular dichroism study. 219
Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors 214
Circular dichroism in drug discovery and development: an abridged review. 197
Naturally inspired molecules as multifunctional agents for Alzheimer's disease treatment 195
Immobilized Enzyme Reactors: an Overview of Applications in Drug Discovery from 2008 to 2018 188
Amaryllidaceae alkaloids from Narcissus pseudonarcissus L. cv. Dutch Master as potential drugs in treatment of Alzheimer's disease 183
Analytical characterization of fruits waste for their valorization as sources of bioactive compounds. 174
(±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease 174
Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets 169
Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. 169
Development of an UHPLC-diode arrays detector (DAD) method for the analysis of polydatin in human plasma 169
Amyloid beta-Peptide 25-35 Self Assembly and Its Inhibition: A Model Undecapeptide System to Gain Atomistic and Secondary Structure Details of the Alzheimer's Disease Process and Treatment 168
Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimers Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography 165
Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer’s disease 163
Fluorinated benzophenone derivatives: balanced multipotent agents for Alzheimer's disease 162
Investigating in vitro amyloid peptide 1−42 aggregation: Impact of higher molecular weight stable adducts 162
An Advanced Multiple Receptor Conformations Virtual Ligand Screening Protocol for the Identification of Novel BACE-1 Inhibitors 159
Human recombinant beta-secretase immobilized enzyme reactor for fast hits’ selection and characterization from a virtual screening library 159
Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death 158
Phenolic and Antioxidant Characterization of Fruit By-Products for Their Nutraceuticals and Dietary Supplements Valorization under a Circular Bio-Economy Approach 157
Structural characterization of p53 isoforms due to the polymorphism at codon 72 by Mass Spectrometry and Circular Dichroism. 154
Analytical approaches in Alzheimer’s disease Drug Discovery 154
Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimer's disease 154
Surface plasmon resonance, fluorescence, and circular dichroism studies for the characterization of the binding of BACE-1 inhibitors 153
Uleine disrupts key enzymatic and non-enzymatic biomarkers that leads to Alzheimer's disease 151
Multifunctional activity of some isoquinoline alkaloids from Corydalis cava tubers on Alzheimer's disease targets 150
Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery? 149
Combined Methodologies for Determining In Vitro Bioavailability of Drugs and Prediction of In Vivo Bioequivalence From Pharmaceutical Oral Formulations 149
A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017 147
Integrated analytical approaches for the characterization of nutraceutical bioactives in microalgae 146
From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold 145
Protein Flexibility in Virtual Screening: The BACE-1 Case Study 144
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects 143
Curcumin derivatives as beta-secretase (BACE1) inhibitors. 140
Circular Dichroism: a Study of Reversible Binding HSA Binding of Lipocrine. 140
Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. 136
Aß42 peptide toxicity on neuronal cells: a lipidomic study in view of Alzheimer’s Disease drug discovery 135
null 135
- Application of an ESI-MS method enabling the discovery of new non-ATP competitive GSK-3beta inhibitors. 131
Fentanyl pharmacokinetics in blood of cancer patients by Gas Chromatography - Mass Spectrometry 129
Application of an ESI-MS method enabling the discovery of new non-ATP competitive GSK-3beta inhibitors. 126
Design, synthesis, in silico and in vitro screening of 1,2,4-thiadiazole analogues as non-peptide inhibitors of beta-secretase. 126
Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks 126
Characterization of polyphenolic composition in Leccinum Scabrum and Leccinum Versipelle mushrooms 125
The role of Chromatography in Alzheimer’s Disease Drug Discovery. 125
Micro-immobilized enzyme reactor based on human recombinant beta secretase (hrBACE-1-microIMER) for liquid chromatography fast screening of inhibitors. 125
Application of ESI-MS method for detailed characterization of GSK-3β inhibitors by monitoring GSM peptide phosphorylation.Angelini Farmaceutici. 125
null 123
A multi-methodological approach for the investigation of β-Amyloid-CORMs interaction: an LC-ESI/MS and Circular Dichroism study. 123
Application of an ESI-QTOF method for the detailed characterization of GSK-3β inhibitors 123
Identification of Novel BACE-1 Inhibitors through an Advanced Structure-Based Virtual Screening Protocol. 122
Design of Experiments and Optimization of Monacolin K Green Extraction from Red Yeast Rice by Ultra-High-Performance Liquid Chromatography 120
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors 120
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease 120
Optical Biosensors and Applications to Drug Discovery and Development in Cancer Research 120
A multi-approach study for BACE-1 inhibitors characterization. 120
ESI-MS and UHPLC combined analytical approaches for determining the kinetics of Glycogen Synthase Kinase-3β 119
Structural characterization of recombinant therapeutic proteins by circular dichroism. 119
Valorization of by-products from agro-foods for pharmaceutical, cosmetic, nutraceutical applications 118
Monitoring GSM peptide phosphorylation by Glycogen Synthase Kinase-3β using Electrospray Ionization Ion Trap Mass Spectrometry (ESI-IT-MS). 114
An immobilized enzyme reactor based on human recombinant betasecretase (hrBACE-1-IMER) for the fast processing of substrates and screening of inhibitors 113
Characterization of essential oil components in cosmetic products by GC-MS. 112
β-Amyloid-CORMs interaction monitoring by LC-ESI/MS and Circular Dichroism studies 112
Surface plasmon resonance assay for BACE-1 inhibitors’ characterization. 111
Synthesis, in vitro biological profiling and in vivo efficacy studies of novel multitarget disease-modifyng anti-Alzheimer drug candidates. 111
Liquid chromatographic enzymatic studies with on-line Beta-secretase immobilized enzyme reactor and 4-(4-dimethylaminophenylazo) benzoic acid/5-[(2-aminoethyl) amino] naphthalene-1-sulfonic acid as fluorogenic substrate 110
null 108
null 106
Integrated analytical methodologies for Alzheimer's disease drug discovery 106
Uleine an indole alkaloid from Himatanthus lancifolius as acetylcholinesterase, butyrylcholinesterase, beta-secretase and beta-amyloid(1-42) spontaneous aggregation inhibitor. 105
Design, Synthesis and Biological profiling of a promising new family of multitarget directed ligands for the treatment of Alzheimer Disease. 104
Synthesis and pharmacological evaluation of a novel class of multi target Huprine-based anti-Alzheimer hybrids 103
Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids 100
null 99
LIPIDOMICS STUDY OF NEUROBLASTOMA CELLS UNDER Aβ1-42 TOXIC INSULT 99
Direct determination of GSK-3β activity and inhibition by UHPLC-UV-vis diode arrays detector (DAD) 98
Simultaneous Multiple MS Binding Assays for the Dopamine, Norepinephrine, and Serotonin Transporters 95
Synthesis, molecular modelling, in vitro biological profiling, and in vivo efficacy studies of a novel family of huprine-based multi-target anti-alzheimer compounds. 95
null 91
Lipidomics of neuroblastoma cells under Aß1-42 toxic insult 89
Optimization of natural compounds on-line screening by immobilized enzyme reactor based on human recombinant betasecretase (hrBACE-1-IMER). 87
Tacrine-benzofunan hybrids as multi-target directed ligands for Alzheimer´s disease treatment 86
Simultaneous MS Binding Assays for Monoamine Transporters. 83
Tacrine-based Multifunctional Agents in Alzheimer's Disease: an Old Story in Continuous Development 79
MICROALGAE: BIOACTIVES EXTRACTION AND CHARACTERIZATION FOR NUTRACEUTICAL USAGE 77
null 77
Valorization of by-products from agri-foods for pharmaceutical, cosmetic, nutraceutical applications 76
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. 75
Totale 13.679
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021392 0 0 0 0 0 0 0 0 0 45 41 306
2021/20221.484 187 40 78 43 130 75 27 108 136 79 314 267
2022/20231.598 154 218 107 227 140 116 37 103 265 63 97 71
2023/2024535 37 79 41 52 43 101 48 36 23 23 32 20
2024/20251.941 77 272 213 138 371 64 167 90 11 88 88 362
2025/20264.686 374 687 426 350 498 308 762 168 890 223 0 0
Totale 13.679